

## Author index

### Volume 282 (1999)

- Aisaka, Y., see Asada, N. **282**, 197  
 Akiyama, T., see Imoto, M. **282**, 77  
 Amin, M., Eckhardt, T., Kapitza, S., Fleckenstein, B., Jung, G., Seissler, J., Weichert, H., Richter, T., Stern, M., Mothes, T., Correlation between tissue transglutaminase antibodies and endomysium antibodies as diagnostic markers of coeliac disease **282**, 219  
 Asada, N., Kitamoto, M., Aisaka, Y., Kawamura, H., Nakanishi, T., Kajiya, G., Horie, Y., Recovery from acute cholestasis associated with erythropoietic protoporphyria treated by antibiotics **282**, 197  
 Astles, J.R., see Lipman, H.B. **282**, 15  
 Bousquet, B., see Le Bricon, T. **282**, 101  
 Bowers, B., see Jones, F.I. **282**, 125  
 Brguljan, P.M., see Cimerman, N. **282**, 211  
 Caputo, M., see Dorizzi, R.M. **282**, 175  
 Cimerman, N., Brguljan, P.M., Krašovec, M., Šuškovič, S., Kos, J., Circadian characteristics of cathepsins B, H, L, and stefins A and B, potential markers for disease, in normal sera **282**, 211  
 Contois, J.H., Gillmor, R.G., Moore, R.E., Contois, L.-R.W., Macer, J.L., Wu, A.H.B., Quantitative determination of cholesterol in lipoprotein fractions by electrophoresis **282**, 1  
 Contois, L.-R.W., see Contois, J.H. **282**, 1  
 Dewitte, K., Stöckl, D., Thienpont, L.M., Measurement of serum sodium and potassium with direct ion-selective electrode systems **282**, 227  
 Dorizzi, R.M., Senna, G., Caputo, M., Likelihood ratios and Fagan's nomogram: valuable but underrated tools for in vitro latex sensitization assessment **282**, 175  
 Doss, M.O., see Kühnel, A. **282**, 45  
 Eckhardt, T., see Amin, M. **282**, 219  
 Fintor, L., see Nagy, B. **282**, 147  
 Fleckenstein, B., see Amin, M. **282**, 219  
 Flock, B., see Mayatepek, E. **282**, 151  
 Fogarty, D.G., see Woodside, J.V. **282**, 157  
 Fryer, A.A., see Jones, F.I. **282**, 125  
 Fuchs, D., see Ledochowski, M. **282**, 115  
 Furuta, I., see Imoto, M. **282**, 77  
 Garnier, J.-P., see Le Bricon, T. **282**, 101  
 Gillmor, R.G., see Contois, J.H. **282**, 1  
 Groß, U., see Kühnel, A. **282**, 45  
 Guibal, F., see Le Bricon, T. **282**, 101  
 Hagen, T., Korson, M.S., Quantification of glutaric acid by isotope dilution mass spectrometry for patients with glutaric acidemia type I: selected ion monitoring vs. selected ion storage **282**, 185  
 Hartmann, W., see Kluge, H.H. **282**, 135  
 Hilgertová, J., see Škrha, J. **282**, 167  
 Horie, Y., see Asada, N. **282**, 197  
 Horiuchi, A., see Imoto, M. **282**, 77  
 Imoto, M., Ishikawa, K., Yamamoto, K., Sinohara, H., Irimajiri, K., Kubo, N., Sakurabayashi, I., Horiuchi, A., Akiyama, T., Ohba, Y., Furuta, I., Occurrence of heavy chain of 7S IgM half-molecule whose NH<sub>2</sub>-terminal sequence is identical with that of κ light chain sequence in patients with Waldenstrom macroglobulinemia **282**, 77

- Irimajiri, K., see Imoto, M. **282**, 77  
Ishikawa, K., see Imoto, M. **282**, 77  
Ishizu, H., see Kitao, T. **282**, 203
- Jacob, K., see Kühnel, A. **282**, 45  
Jones, F.I., Ramachandran, S., Lear, J., Smith, A., Bowers, B., Ollier, W.E.R., Jones, P., Fryer, A.A., Strange, R.C., The melanocyte stimulating hormone receptor polymorphism: association of the V92M and A294H alleles with basal cell carcinoma **282**, 125  
Jones, P., see Jones, F.I. **282**, 125  
Jung, G., see Amin, M. **282**, 219
- Kajiyama, G., see Asada, N. **282**, 197  
Kapitza, S., see Amin, M. **282**, 219  
Karádi, I., see Nagy, B. **282**, 147  
Kawamura, H., see Asada, N. **282**, 197  
Kitamoto, M., see Asada, N. **282**, 197  
Kitao, T., Miyaishi, S., Ishizu, H., Effects of pH and urea on the determination of urinary myoglobin concentration by an enzyme immunoassay **282**, 203  
Kluge, H.H., Kluge, W.H., Hartmann, W., An inhibitor-free assay of acetylcholinesterase and butyrylcholinesterase in the cerebrospinal fluid **282**, 135  
Kluge, W.H., see Kluge, H.H. **282**, 135  
Kodama, H., see Zhang, J. **282**, 89  
Korson, M.S., see Hagen, T. **282**, 185  
Kos, J., see Cimerman, N. **282**, 211  
Krašovec, M., see Cimerman, N. **282**, 211  
Kubo, N., see Imoto, M. **282**, 77  
Kühnel, A., Groß, U., Jacob, K., Doss, M.O., Studies on coproporphyrin isomers in urine and feces in the porphyrias **282**, 45
- Le Bricon, T., Stoitchkov, K., Letellier, S., Guibal, F., Spy, J., Garnier, J.-P., Bousquet, B., Simultaneous analysis of tyrosinase mRNA and markers of tyrosinase activity in the blood of patients with metastatic melanoma **282**, 101  
Lear, J., see Jones, F.I. **282**, 125  
Ledochowski, M., Murr, C., Widner, B., Fuchs, D., Association between insulin resistance, body mass and neopterin concentrations **282**, 115  
Letellier, S., see Le Bricon, T. **282**, 101  
Lightbody, J.H., see Woodside, J.V. **282**, 157  
Lipman, H.B., Astles, J.R., Estimating the linear analytic range **282**, 15  
Loughrey, C.M., see Woodside, J.V. **282**, 157
- Macer, J.L., see Contois, J.H. **282**, 1  
Makino, T., A simple and sensitive colorimetric assay of zinc in serum using cationic porphyrin **282**, 65  
Martella, M., see Murgia, A. **282**, 229  
Maxwell, A.P., see Woodside, J.V. **282**, 157  
Mayatepek, E., Flock, B., Increased urinary excretion of LTB<sub>4</sub> and  $\omega$ -carboxy-LTB<sub>4</sub> in patients with Zellweger syndrome **282**, 151  
Miyaishi, S., see Kitao, T. **282**, 203  
Moore, R.E., see Contois, J.H. **282**, 1  
Mothes, T., see Amin, M. **282**, 219  
Murgia, A., Polli, R., Martella, M., Vinanzi, C., Opocher, G., Corrigendum to "Molecular diagnosis of inherited diseases". [Clinica Chimica Acta 280 (1999) 73-80] **282**, 229  
Murr, C., see Ledochowski, M. **282**, 115
- Nagy, B., Karádi, I., Fintor, L., Rigó Jr, J., Romics, L., Papp, Z., Apolipoprotein E gene polymorphism frequencies in a sample of healthy Hungarians **282**, 147  
Nakanishi, T., see Asada, N. **282**, 197
- Ohba, Y., see Imoto, M. **282**, 77  
Olczak, M., Olczak, T., Oligosaccharides released by hydrazinolysis from Tamm-Horsfall protein of various human donors contain similar high-mannose glycans **282**, 35  
Olczak, T., see Olczak, M. **282**, 35  
Ollier, W.E.R., see Jones, F.I. **282**, 125  
Opocher, G., see Murgia, A. **282**, 229
- Papp, Z., see Nagy, B. **282**, 147  
Polli, R., see Murgia, A. **282**, 229
- Rainwater, D.L., Stability of apolipoprotein(a) isoform phenotype to postmortem conditions **282**, 59  
Ramachandran, S., see Jones, F.I. **282**, 125  
Richter, T., see Amin, M. **282**, 219  
Rigó Jr, J., see Nagy, B. **282**, 147  
Romics, L., see Nagy, B. **282**, 147
- Sakurabayashi, I., see Imoto, M. **282**, 77  
Seissler, J., see Amin, M. **282**, 219  
Senna, G., see Dorizzi, R.M. **282**, 175  
Seto, K., see Zhang, J. **282**, 89  
Sinohara, H., see Imoto, M. **282**, 77  
Škrha, J., Hilgertová, J., Relationship of serum N-acetyl- $\beta$ -glucosaminidase activity to oxidative stress in diabetes mellitus **282**, 167  
Smith, A., see Jones, F.I. **282**, 125  
Spy, J., see Le Bricon, T. **282**, 101  
Stern, M., see Amin, M. **282**, 219  
Stöckl, D., see Dewitte, K. **282**, 227

- Stoitchkov, K., see Le Bricon, T. **282**, 101  
 Strange, R.C., see Jones, F.I. **282**, 125  
 Sugahara, K., see Zhang, J. **282**, 89  
 Šuškovič, S., see Cimerman, N. **282**, 211
- Thienpont, L.M., see Dewitte, K. **282**, 227
- Ushikoshi, I., see Zhang, J. **282**, 89  
 Ushikoshi, S., see Zhang, J. **282**, 89
- Vinanzi, C., see Murgia, A. **282**, 229
- Weichert, H., see Amin, M. **282**, 219  
 Widner, B., see Ledochowski, M. **282**, 115  
 Woodside, J.V., Fogarty, D.G., Lightbody, J.H.,  
 Loughrey, C.M., Yarnell, J.W.G., Maxwell, A.P.,  
 Young, I.S., Homocysteine and B-group vita-  
 mins in renal transplant patients **282**, 157  
 Wu, A.H.B., see Contois, J.H. **282**, 1
- Yamamoto, K., see Imoto, M. **282**, 77  
 Yarnell, J.W.G., see Woodside, J.V. **282**, 157  
 Young, I.S., see Woodside, J.V. **282**, 157
- Zhang, J., Sugahara, K., Ushikoshi, I., Ushikoshi,  
 S., Seto, K., Kodama, H., Effect of water  
 extracts of *Rhizopus delemar* on the stimulus  
 coupled responses of neutrophils and their  
 modulation by various protein kinase  
 inhibitors **282**, 89





## Subject index

### Volume 282 (1999)

**A294H**; Melanocyte stimulating hormone receptor; Allele; Susceptibility; Basal cell carcinoma; V92M **282**, 125

**Acetylcholinesterase**; Butyrylcholinesterase; Cerebrospinal fluid; Inhibitor-free test **282**, 135

**Acute hepatic porphyrias**; Urinary and fecal coproporphyrin isomers I–IV; Differential diagnosis; Erythropoietic porphyrias; Chronic hepatic porphyrias; Ion-pair high-performance liquid chromatography (HPLC) **282**, 45

**Allele**; Melanocyte stimulating hormone receptor; Susceptibility; Basal cell carcinoma; V92M; A294H **282**, 125

**Antibiotics**; Porphyria; Erythropoietic protoporphyria; Cholestasis; Treatment; Sepsis; Infection **282**, 197

**Apo(a)**; Postmortem; Lp(a); Protein degradation **282**, 59

**Apolipoprotein E**; Polymerase chain reaction; Restriction length polymorphism; Gene polymorphism **282**, 147

**Basal cell carcinoma**; Melanocyte stimulating hormone receptor; Allele; Susceptibility; V92M; A294H **282**, 125

**Body mass**; Non-insulin-dependent diabetes mellitus; Insulin resistance; Tumor necrosis factor- $\alpha$ ; Interferon- $\gamma$ ; Neopterin **282**, 115

**Butyrylcholinesterase**; Acetylcholinesterase; Cerebrospinal fluid; Inhibitor-free test **282**, 135

**Cathepsins B, H, L**; Stefins A, B; Serum levels; 24-h variations **282**, 211

**Cerebrospinal fluid**; Acetylcholinesterase; Butyrylcholinesterase; Inhibitor-free test **282**, 135

**Cholestasis**; Porphyria; Erythropoietic protoporphyria; Treatment; Antibiotics; Sepsis; Infection **282**, 197

**Cholesterol**; Lipoprotein electrophoresis; Very low density lipoproteins; Low density lipoproteins; High density lipoproteins; Lipoprotein(a) **282**, 1

**Chronic hepatic porphyrias**; Urinary and fecal coproporphyrin isomers I–IV; Differential diagnosis; Erythropoietic porphyrias; Acute hepatic porphyrias; Ion-pair high-performance liquid chromatography (HPLC) **282**, 45

**Cobalamin**; Renal transplant patients; Homocysteine; Folate **282**, 157

**Coeliac disease**; Tissue transglutaminase; Endomysium antibodies **282**, 219

**Colorimetry**; Serum zinc; Porphyrin reagent; Highly sensitive method; Trace analysis **282**, 65

**Correlation**; Linear range; Regression; Estimation; Monte Carlo method **282**, 15

- Diabetes mellitus;** N-acetyl- $\beta$ -glucosaminidase; Oxidative stress **282, 167**
- Differential diagnosis;** Urinary and fecal coproporphyrin isomers I-IV; Erythropoietic porphyrias; Acute hepatic porphyrias; Chronic hepatic porphyrias; Ion-pair high-performance liquid chromatography (HPLC) **282, 45**
- Direct ISE;** Sodium; Potassium; Reference method; Serum; Standardization **282, 227**
- L-DOPA;** Tyrosinase; RT-PCR; Melanoma; Metastases **282, 101**
- Endomysium antibodies;** Tissue transglutaminase; Coeliac disease **282, 219**
- Enzyme immunoassay;** pH; Urea; Myoglobin **282, 203**
- Erythropoietic porphyrias;** Urinary and fecal coproporphyrin isomers I-IV; Differential diagnosis; Acute hepatic porphyrias; Chronic hepatic porphyrias; Ion-pair high-performance liquid chromatography (HPLC) **282, 45**
- Erythropoietic protoporphyria;** Porphyria; Cholestasis; Treatment; Antibiotics; Sepsis; Infection **282, 197**
- Estimation;** Linear range; Regression; Correlation; Monte Carlo method **282, 15**
- Evidence-based medicine;** Latex allergy; ROC analysis **282, 175**
- Folate;** Renal transplant patients; Homocysteine; Cobalamin **282, 157**
- GC-MS;** Selected ion monitoring; Selected ion storage; Glutaric acid **282, 185**
- Gene polymorphism;** Polymerase chain reaction; Restriction length polymorphism; Apolipoprotein E **282, 147**
- Glutaric acid;** GC-MS; Selected ion monitoring; Selected ion storage **282, 185**
- N-glycans;** Tamm-Horsfall protein; High-mannose glycans; Kidney **282, 35**
- Half-molecule 7S IgM(HM 7S IgM);** Waldenstrom macroglobulinemia; NH<sub>2</sub>-terminal amino acid sequence **282, 77**
- High density lipoproteins;** Cholesterol; Lipoprotein electrophoresis; Very low density lipoproteins; Low density lipoproteins; Lipoprotein(a) **282, 1**
- High-mannose glycans;** Tamm-Horsfall protein; N-glycans; Kidney **282, 35**
- Highly sensitive method;** Serum zinc; Porphyrin reagent; Colorimetry; Trace analysis **282, 65**
- Homocysteine;** Renal transplant patients; Folate; Cobalamin **282, 157**
- Infection;** Porphyria; Erythropoietic protoporphyria; Cholestasis; Treatment; Antibiotics; Sepsis **282, 197**
- Inhibitor-free test;** Acetylcholinesterase; Butyrylcholinesterase; Cerebrospinal fluid **282, 135**
- Insulin resistance;** Non-insulin-dependent diabetes mellitus; Tumor necrosis factor- $\alpha$ ; Interferon- $\gamma$ ; Neopterin; Body mass **282, 115**
- Interferon- $\gamma$ ;** Non-insulin-dependent diabetes mellitus; Insulin resistance; Tumor necrosis factor- $\alpha$ ; Neopterin; Body mass **282, 115**
- Ion-pair high-performance liquid chromatography (HPLC);** Urinary and fecal coproporphyrin isomers I-IV; Differential diagnosis; Erythropoietic porphyrias; Acute hepatic porphyrias; Chronic hepatic porphyrias **282, 45**
- Kidney;** Tamm-Horsfall protein; High-mannose glycans; N-glycans **282, 35**
- Latex allergy;** Evidence-based medicine; ROC analysis **282, 175**
- Leukotrienes;** Long-chain acyl CoA dehydrogenase deficiency; Mitochondria; Peroxisomes; Zellweger syndrome **282, 151**
- Linear range;** Regression; Correlation; Estimation; Monte Carlo method **282, 15**
- Lipoprotein electrophoresis;** Cholesterol; Very low density lipoproteins; Low density lipoproteins; High density lipoproteins; Lipoprotein(a) **282, 1**

- Lipoprotein(a);** Cholesterol; Lipoprotein electrophoresis; Very low density lipoproteins; Low density lipoproteins; High density lipoproteins **282, 1**
- Long-chain acyl CoA dehydrogenase deficiency;** Leukotrienes; Mitochondria; Peroxisomes; Zellweger syndrome **282, 151**
- Low density lipoproteins;** Cholesterol; Lipoprotein electrophoresis; Very low density lipoproteins; High density lipoproteins; Lipoprotein(a) **282, 1**
- Lp(a);** Postmortem; Apo(a); Protein degradation **282, 59**
- Melanocyte stimulating hormone receptor;** Allele; Susceptibility; Basal cell carcinoma; V92M; A294H **282, 125**
- Melanoma;** Tyrosinase; RT-PCR; L-DOPA; Metastases **282, 101**
- Metastases;** Tyrosinase; RT-PCR; L-DOPA; Melanoma **282, 101**
- Mitochondria;** Leukotrienes; Long-chain acyl CoA dehydrogenase deficiency; Peroxisomes; Zellweger syndrome **282, 151**
- Monte Carlo method;** Linear range; Regression; Correlation; Estimation **282, 15**
- Myoglobin;** Enzyme immunoassay; pH; Urea **282, 203**
- N-acetyl- $\beta$ -glucosaminidase;** Oxidative stress; Diabetes mellitus **282, 167**
- NH<sub>2</sub>-terminal amino acid sequence;** Half-molecule 7S IgM(HM 7S IgM); Waldenstrom macroglobulinemia **282, 77**
- Neopterin;** Non-insulin-dependent diabetes mellitus; Insulin resistance; Tumor necrosis factor- $\alpha$ ; Interferon- $\gamma$ ; Body mass **282, 115**
- Neutrophil;** *Rhizopus deleamar*; Superoxide **282, 89**
- Non-insulin-dependent diabetes mellitus;** Insulin resistance; Tumor necrosis factor- $\alpha$ ; Interferon- $\gamma$ ; Neopterin; Body mass **282, 115**
- Oxidative stress;** N-acetyl- $\beta$ -glucosaminidase; Diabetes mellitus **282, 167**
- Peroxisomes;** Leukotrienes; Long-chain acyl CoA dehydrogenase deficiency; Mitochondria; Zellweger syndrome **282, 151**
- pH;** Enzyme immunoassay; Urea; Myoglobin **282, 203**
- Polymerase chain reaction;** Restriction length polymorphism; Apolipoprotein E; Gene polymorphism **282, 147**
- Porphyria;** Erythropoietic protoporphyria; Cholestasis; Treatment; Antibiotics; Sepsis; Infection **282, 197**
- Porphyrin reagent;** Serum zinc; Highly sensitive method; Colorimetry; Trace analysis **282, 65**
- Postmortem;** Lp(a); Apo(a); Protein degradation **282, 59**
- Potassium;** Direct ISE; Sodium; Reference method; Serum; Standardization **282, 227**
- Protein degradation;** Postmortem; Lp(a); Apo(a) **282, 59**
- Rhizopus deleamar*;** Neutrophil; Superoxide **282, 89**
- ROC analysis;** Latex allergy; Evidence-based medicine **282, 175**
- Reference method;** Direct ISE; Sodium; Potassium; Serum; Standardization **282, 227**
- Regression;** Linear range; Correlation; Estimation; Monte Carlo method **282, 15**
- Renal transplant patients;** Homocysteine; Folate; Cobalamin **282, 157**
- Restriction length polymorphism;** Polymerase chain reaction; Apolipoprotein E; Gene polymorphism **282, 147**
- RT-PCR;** Tyrosinase; L-DOPA; Melanoma; Metastases **282, 101**
- Selected ion monitoring;** GC-MS; Selected ion storage; Glutaric acid **282, 185**

- Selected ion storage;** GC-MS; Selected ion monitoring; Glutaric acid **282**, 185
- Sepsis;** Porphyria; Erythropoietic protoporphyria; Cholestasis; Treatment; Antibiotics; Infection **282**, 197
- Serum;** Direct ISE; Sodium; Potassium; Reference method; Standardization **282**, 227
- Serum levels;** Cathepsins B, H, L; Stepins A, B; 24-h variations **282**, 211
- Serum zinc;** Porphyrin reagent; Highly sensitive method; Colorimetry; Trace analysis **282**, 65
- Sodium;** Direct ISE; Potassium; Reference method; Serum; Standardization **282**, 227
- Standardization;** Direct ISE; Sodium; Potassium; Reference method; Serum **282**, 227
- Stepins A, B;** Cathepsins B, H, L; Serum levels; 24-h variations **282**, 211
- Superoxide;** *Rhizopus delemar*; Neutrophil **282**, 89
- Susceptibility;** Melanocyte stimulating hormone receptor; Allele; Basal cell carcinoma; V92M; A294H **282**, 125
- Tamm-Horsfall protein;** High-mannose glycans; N-glycans; Kidney **282**, 35
- Tissue transglutaminase;** Endomysium antibodies; Coeliac disease **282**, 219
- Trace analysis;** Serum zinc; Porphyrin reagent; Highly sensitive method; Colorimetry **282**, 65
- Treatment;** Porphyria; Erythropoietic protoporphyria; Cholestasis; Antibiotics; Sepsis; Infection **282**, 197
- Tumor necrosis factor- $\alpha$ ;** Non-insulin-dependent diabetes mellitus; Insulin resistance; Interferon- $\gamma$ ; Neopterin; Body mass **282**, 115
- Tyrosinase;** RT-PCR; L-DOPA; Melanoma; Metastases **282**, 101
- Urea;** Enzyme immunoassay; pH; Myoglobin **282**, 203
- Urinary and fecal coproporphyrin isomers I-IV;** Differential diagnosis; Erythropoietic porphyrias; Acute hepatic porphyrias; Chronic hepatic porphyrias; Ion-pair high-performance liquid chromatography (HPLC) **282**, 45
- V92M;** Melanocyte stimulating hormone receptor; Allele; Susceptibility; Basal cell carcinoma; A294H **282**, 125
- 24-h variations;** Cathepsins B, H, L; Stepins A, B; Serum levels **282**, 211
- Very low density lipoproteins;** Cholesterol; Lipoprotein electrophoresis; Low density lipoproteins; High density lipoproteins; Lipoprotein(a) **282**, 1
- Waldenstrom macroglobulinemia;** Half-molecule 7S IgM(HM 7S IgM); NH<sub>2</sub>-terminal amino acid sequence **282**, 77
- Zellweger syndrome;** Leukotrienes; Long-chain acyl CoA dehydrogenase deficiency; Mitochondria; Peroxisomes **282**, 151